Approval · Notice of Compliance 16203 · 2014
TRINTELLIX: Notice of Compliance 16203
Issued October 22, 2014
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 16203
- Date
- October 22, 2014
- Company
- Lundbeck Canada IncSt-Laurent, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
- Therapeutic class
- Antidepressant
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TRINTELLIX | 02432919 | Marketed |
| TRINTELLIX | 02432927 | Marketed |
| TRINTELLIX | 02432935 | Approved |
| TRINTELLIX | 02432943 | Marketed |
Medicinal ingredients
- VORTIOXETINE HYDROBROMIDE 5 MG per TAB
- VORTIOXETINE HYDROBROMIDE 10 MG per TAB
- VORTIOXETINE HYDROBROMIDE 15 MG per TAB
- VORTIOXETINE HYDROBROMIDE 20 MG per TAB